Gabelli Funds’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Gabelli Funds’s Portfolio SLXNW Stock Details SLXNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$927	Hold	30,496	–	–	﹤0.01%	1284
2026 Q1	$619	Hold	30,496	–	–	﹤0.01%	1263
2025 Q4	$793	Hold	30,496	–	–	﹤0.01%	1244
2025 Q3	$1.07K	Hold	30,496	–	–	﹤0.01%	1241
2025 Q2	$1.25K	Hold	30,496	–	–	﹤0.01%	1218
2025 Q1	$2.33K	Buy	+30,496	New	+$1.86K	﹤0.01%	1083
2024 Q4	–	Sell	-30,496	Closed	-$967	–	1115
2024 Q3	$967	Buy	+30,496	New	+$1.77K	﹤0.01%	1091

Other funds holding SLXNW

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.88B AUM 54.21% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

SBLIC

Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Gabelli Funds's SLXNW Position: Q2 2026 in Review

Gabelli Funds held its Silexion Therapeutics Warrant (SLXNW) position steady in Q2 2026 at 30,496 shares worth $927. The position accounts for ﹤0.01% of the portfolio, ranked #1284.

Gabelli Funds first reported a position in SLXNW in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.33K in Q1 2025. 19 funds tracked by Wall St. Rank hold SLXNW as of Q2 2026.

Gabelli Funds held 30,496 shares of Silexion Therapeutics Warrant worth $927 as of Q2 2026.
Gabelli Funds left its Silexion Therapeutics Warrant share count unchanged in Q2 2026.
Silexion Therapeutics Warrant made up ﹤0.01% of Gabelli Funds's portfolio in Q2 2026, its #1284 holding.
Gabelli Funds first reported a position in Silexion Therapeutics Warrant in Q3 2024 and has held it in 7 quarters since.
Gabelli Funds's Silexion Therapeutics Warrant position peaked at $2.33K in Q1 2025.
19 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q2 2026.

Based on Gabelli Funds's 13F filing for Q2 2026, filed 12 Aug 2026.